Intervention Review

You have free access to this content

Pharmacological treatment for memory disorder in multiple sclerosis

  1. Dian He1,
  2. Yun Zhang2,
  3. Shuai Dong3,
  4. Dongfeng Wang3,
  5. Xiangdong Gao3,
  6. Hongyu Zhou4,*

Editorial Group: Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group

Published Online: 17 DEC 2013

Assessed as up-to-date: 25 JUL 2013

DOI: 10.1002/14651858.CD008876.pub3


How to Cite

He D, Zhang Y, Dong S, Wang D, Gao X, Zhou H. Pharmacological treatment for memory disorder in multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD008876. DOI: 10.1002/14651858.CD008876.pub3.

Author Information

  1. 1

    Affiliated Hospital of Guiyang Medical College, Department of Neurology, Guiyang, Guizhou Province, China

  2. 2

    Jinan No. 6 People's Hospital, Clinical Laboratory, Jinan, Shandong Province, China

  3. 3

    Jinan No. 6 People's Hospital, Department of Neurology, Jinan, Shandong Province, China

  4. 4

    West China Hospital, Sichuan University, Department of Neurology, Chengdu, Sichuan, China

*Hongyu Zhou, Department of Neurology, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, 610041, China. Hyzhou98@yahoo.com.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 17 DEC 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
  6. References to other published versions of this review
Krupp 2004 {published data only}
  • Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004;63(9):1579-85.
Krupp 2011 {published data only}
  • Krupp LB, Christodoulou C, Melville P, Scherl WF, Pai LY, Muenz LR, et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology 2011;76(17):1500-7.
Lovera 2007 {published data only}
  • Lovera J, Bagert B, Smoot K, Morris CD, Frank R, Bogardus K, et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. Multiple Sclerosis 2007;13(3):376-85.
Lovera 2010 {published data only}
  • Lovera JF, Frohman E, Brown TR, Bandari D, Nguyen L, Yadav V, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Multiple Sclerosis 2010;16(6):715-23.
Lovera 2012 {published data only}
  • Lovera JF, Kim E, Heriza E, Fitzpatrick M, Hunziker J, Turner AP, et al. Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial. Neurology 2012;79(12):1278-84.
Mäurer 2013 {published data only}
  • Mäurer M, Ortler S, Baier M, Meergans M, Scherer P, Hofmann W, et al. Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients. Multiple Sclerosis 2013;19(5):631-8.
Shaygannejad 2008 {published data only}
  • Shaygannejad V, Janghorbani M, Ashtari F, Zanjani HA, Zakizade N. Effects of rivastigmine on memory and cognition in multiple sclerosis. Canadian Journal of Neurological Sciences 2008;35(4):476-81.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
  6. References to other published versions of this review
Aragona 2009 {published data only}
  • Aragona M, Onesti E, Tomassini V, Conte A, Gupta S, Gilio F, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clinical Neuropharmacology 2009;32(1):41-7.
Barak 1999 {published data only}
  • Barak Y, Gabbay U, Gilad R, Sarova-Pinhas I, Achiron A. Neuropsychiatric assessment as a secondary outcome measure in a multiple sclerosis intravenous immunoglobulin (IVIg) trial. International Journal of Psychiatry in Clinical Practice 1999;3:31-4.
Barak 2002 {published data only}
Benedict 2008 {published data only}
  • Benedict RH, Munschauer F, Zarevics P, Erlanger D, Rowe V, Feaster T, et al. Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients. Journal of Neurology 2008;255(6):848-52.
Bever 1996 {published data only}
  • Bever CT Jr, Anderson PA, Leslie J, Panitch HS, Dhib-Jalbut S, Khan OA, et al. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 1996;47(6):1457-62.
Bosca 2004 {published data only}
  • Bosca I, Bueno A, Gadea M, Casanova B, Coret F. Donepezile and cognitive impairment in multiple sclerosis: a double-blind pilot study. Multiple Sclerosis 2004;10(Suppl 2):S150.
Bruce 2012 {published data only}
  • Bruce J, Hancock L, Roberg B, Brown A, Henkelman E, Lynch S. Impact of armodafinil on cognition in multiple sclerosis: a randomized, double-blind crossover pilot study. Cognitive and Behavioral Neurology 2012;25(3):107-14.
Cabrera-Gomez 2003 {published data only}
  • Cabrera-Gomez JA, Echazabal-Santana N, Porrero-Martin P, Valenzuela-Silva C, Rodriguez CA, Fuentes-Suarez I, et al . Interferon-alpha2b recombinant improved the cognitive dysfunction in patients with relapsing remitting multiple sclerosis. Revista de Neurologia 2003;37(3):214-20.
Christodoulou 2006 {published data only}
  • Christodoulou C, Melville P, Scherl WF, Macallister WS, Elkins LE, Krupp LB. Effects of donepezil on memory and cognition in multiple sclerosis. Journal of Neurological Sciences 2006;245(1-2):127-36.
Cohen 1989 {published data only}
  • Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Archives of Neurology 1989;46(6):676-80.
Cohen 2002 {published data only}
  • Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59(5):679-87.
Cohen 2010 {published data only}
  • Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine 2010;362(5):402-15.
Comi 2012 {published data only}
  • Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. New England Journal of Medicine 2012;366(11):1000-9.
Decoo 2004 {published data only}
  • Decoo D, on behalf of the MS Rehab Study Group. Effects of donepezil in multiple sclerosis: a single-centre trial. Multiple Sclerosis 2004;10(Suppl 2):S150.
Fischer 1994 {published data only}
  • Fischer JS, Goodkin DE, Rudick RA, Perkins KK, Barilla DY, Daughtry MM, et al. Low dose (7.5 mg) oral methotrexate improves neurophysiological function in patients with chronic progressive multiple sclerosis. Annals of Neurology 1994;36:289.
Fischer 2000 {published data only}
Flechter 2007 {published data only}
  • Flechter S, Vardi J, Finkelstein Y, Pollak L. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study. The Israel Medical Association Journal 2007;9(6):457-9.
Geisler 1996 {published data only}
  • Geisler MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Archives of Neurology 1996;53(2):185-8.
Greene 2000 {published data only}
  • Greene YM, Tariot PN, Wishart H, Cox C, Holt CJ, Schwid S, et al. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. Journal of Clinical Psychopharmacology 2000;20(3):350-6.
Harel 2009 {published data only}
  • Harel Y, Appleboim N, Lavie M, Achiron A. Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process. Journal of Neurological Sciences 2009;276(1-2):38-40.
Havrdova 2006 {published data only}
  • Havrdova E. The effects of natalizumab on a test of cognitive function in patients with relapsing multiple sclerosis (MS) [abstract]. European Journal of Neurology 2006;13(Suppl 2):307.
Honarmand 2011 {published data only}
  • Honarmand K, Tierney MC, O'Connor P, Feinstein A. Effects of cannabis on cognitive function in patients with multiple sclerosis. Neurology 2011;76(13):1153-60.
Huolman 2011 {published data only}
  • Huolman S, Hämäläinen P, Vorobyev V, Ruutiainen J, Parkkola R, Laine T, et al. The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue. Multiple Sclerosis 2011;17(11):1351-61.
Iaffaldano 2012 {published data only}
  • Iaffaldano P, Viterbo RG, Paolicelli D, Lucchese G, Portaccio E, Goretti B, et al. Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. PLoS One 2012;7(4):e35843.
Jeffery 2011 {published data only}
  • Jeffery D, Comi G, Kappos L, Montalban X, Boyko A, Filippi M. Laquinimod's impact on patient-reported fatigue and functional status: results from Allegro, a placebo-controlled phase III trial for relapsing-remitting multiple sclerosis. Multiple Sclerosis 2011;17:S313-4.
Kappos 2010 {published data only}
  • Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine 2010;362(5):387-401.
Krause 2012 {published data only}
  • Krause I, Kern S, Schultheiss T, Horntrich A, Hanso H, Thomas K, et al. Cognitive dysfunction in relapsing-remitting multiple sclerosis: relation to quality of life and longitudinal changes under treatment with natalizumab. Multiple Sclerosis 2012;18:S46.
Krupp 1999 {published data only}
  • Krupp LB, Elkins LE, Scheffer S, Smiroldo J, Coyle PK. Donepezil for the treatment of memory impairments in multiple sclerosis. Neurology 1999;52(Suppl 2):A137.
Lacy 2013 {published data only}
  • Lacy M, Hauser M, Pliskin N, Assuras S, Valentine MO, Reder A. The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Multiple Sclerosis 2013;19(13):1765-72.
Lang 2012 {published data only}
Lange 2009 {published data only}
Mattioli 2011a {published data only}
  • Mattioli F, Stampatori C, Capra R. The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study. Neurological Sciences 2011;32(1):83-8.
Mattioli 2011b {published data only}
Melanson 2010 {published data only}
  • Melanson M, Grossberndt A, Klowak M, Leong C, Frost EE, Prout M, et al. Fatigue and cognition in patients with relapsing multiple sclerosis treated with interferon beta. International Journal of Neuroscience 2010;120:631-40.
Miller 2011 {published data only}
  • Miller A, O'Connor P, Wolinsky J, Confavreux C, Comi G, Kappos L, et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase III trial (TEMSO). Multiple Sclerosis 2011;17:S182.
Möller 2011 {published data only}
  • Möller F, Poettgen J, Broemel F, Neuhaus A, Daumer M, Heesen C.  HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. Multiple Sclerosis 2011;17(8):1002-9.
Montalban 2009 {published data only}
  • Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, Río J, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Multiple Sclerosis 2009;15(10):1195-205.
Morrow 2009 {published data only}
  • Morrow SA, Kaushik T, Zarevics P, Erlanger D, Bear MF, Munschauer FE, et al. The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial. Journal of Neurology 2009;256(7):1095-102.
Morrow 2013 {published data only}
  • Morrow SA, Smerbeck A, Patrick K, Cookfair D, Weinstock-Guttman B, Benedict RH. Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study. Journal of Neurology 2013;260(2):489-97.
Oliveri 1998 {published data only}
  • Oliveri RL, Sibilia G, Valentino P, Russo C, Romeo N, Quattrone A. Pulsed methylprednisolone induces a reversible impairment of memory in patients with relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica 1998;97(6):366-9.
Panitch 2004 {published data only}
  • Panitch H, Miller A, Paty D, Weinshenker B, North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63(10):1788-95.
Patti 2009 {published data only}
  • Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Lijoi F, et al. Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsing-remitting multiple sclerosis: 2-year results from the COGIMUS study. Therapeutic Advances in Neurological Disorders 2009;2(2):67-77.
Patti 2010 {published data only}
  • Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, et al. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis 2010;16(1):68-77.
Pliskin 1994 {published data only}
  • Pliskin NH, Towle VL, Hamer DP, Reder AT, Noronha A, Pietre S, et al. The effects of interferon-beta on cognitive function in multiple sclerosis. Annals of Neurology 1994;36:326.
Pliskin 1996 {published data only}
  • Pliskin NH, Hamer DP, Goldstein DS, Towle VL, Reder AT, Noronha A, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996;47(6):1463-8.
Portaccio 2013 {published data only}
Rorie 2001 {published data only}
  • Rorie KD, Stump DA, Jeffery DR, Winston Salem NC. Effects of donepezil on cognitive function in patients with multiple sclerosis. Neurology 2001;56(Suppl 3):A99.
Rossini 2011 {published data only}
  • Rossini PM, Pasqualetti P, Pozzilli C, Grasso MG, Millefiorini E, Graceffa A, et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Multiple Sclerosis 2001;7(6):354-8.
Rudick 2006 {published data only}
  • Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New England Journal of Medicine 2006;354(9):911-23.
Sailer 2000 {published data only}
  • Sailer M, Heinze HJ, Schoenfeld MA, Hauser U, Smid HG. Amantadine influences cognitive processing in patients with multiple sclerosis. Pharmacopsychiatry 2000;33(1):28-37.
Schröder 2011 {published data only}
  • Schröder A, Klotz P, Lee DH, Gold R, Linker RA. Stability of cognitive functions under mitoxantrone therapy in patients with progressive multiple sclerosis: a pilot analysis. Clinical Neurology and Neurosurgery 2011;113(7):527-30.
Schwid 2007 {published data only}
  • Schwid SR, Goodman AD, Weinstein A, McDermott MP, Johnson KP for the Copaxone Study Group. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. Journal of Neurological Sciences 2007;255(1-2):57-63.
Selby 1998 {published data only}
  • Selby MJ, Ling N, Williams JM, Dawson A. Interferon beta 1-b in verbal memory functioning of patients with relapsing-remitting multiple sclerosis. Perceptual and Motor Skills 1998;86(3 Pt 1):1099-106.
Selmaj 2012 {published data only}
  • Selmaj K, Havrdova E, Gold R, Greenberg S, Umans K, Elkins J. Daclizumab Hyp monotherapy improved health-related quality of life parameters in relapsing-remitting multiple sclerosis: findings of the SELECT trial. Neurology 2012; Vol. 78.
Smits 1994 {published data only}
  • Smits RC, Emmen HH, Bertelsmann FW, Kulig BM, van Loenen AC, Polman CH. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology 1994;44(9):1701-5.
Sumowski 2011 {published data only}
  • Sumowski JF, Chiaravalloti N, Erlanger D, Kaushik T, Benedict RH, DeLuca J. L-amphetamine improves memory in MS patients with objective memory impairment. Multiple Sclerosis 2011;17(9):1141-5.
Uttner 2005 {published data only}
Villoslada 2009 {published data only}
Wade 2004 {published data only}
  • Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis 2004;10(4):434-41.
Weinstein 1999 {published data only}
  • Weinstein A, Schwid SR, Schiffer RB, McDermott MP, Giang DW, Goodman AD. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Archives of Neurology 1999;56(3):319-24.
Weinstock-Guttman 2012a {published data only}
  • Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology 2012;259(5):898-905.
Weinstock-Guttman 2012b {published data only}
  • Weinstock-Guttman B, Cree B, de Seze J, Fox R, Gold R, Hartung H, et al. Effects of a 24-week natalizumab treatment interruption on quality of life, fatigue, and cognition: results from the RESTORE Study. Neurology 2012; Vol. 78:P06.171.
Wilken 2004 {published data only}
  • Wilken J, Kane R, Sullivan C, Kane H, Rossman S, Lawson J, et al. Combination therapy (Provigil + Avonex) in the treatment of cognitive problems in MS [abstract]. International Journal of MS Care 2004;6:68-9.
Wilken 2008 {published data only}
  • Wilken JA, Sullivan C, Wallin M, Rogers C, Kane RL, Rossman H, et al. Treatment of multiple sclerosis-related cognitive problems with adjunctive modafinil: rationale and preliminary supportive data. International Journal of MS Care 2008;10:1-10.
Zéphir 2005 {published data only}
  • Zéphir H, de Seze J, Dujardin K, Dubois G, Cabaret M, Bouillaguet S, et al. One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis. Multiple Sclerosis 2005;11(3):360-3.
Zéphir 2008 {published data only}
  • Zéphir H, de Sèze J, Dujardin K, Dubois G, Cabaret M, Bouillaguet S, et al. Cognitive impact of mitoxantrone and methylprednisolone in multiple sclerosis: an open label study. Revue Neurologique (Paris) 2008;164(1):47-52.

References to studies awaiting assessment

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
  6. References to other published versions of this review
NCT01074619 {unpublished data only}
  • NCT01074619. Study on cognitive disorders of multiple sclerosis. clinicaltrials.gov/ct2/show/NCT01074619 (accessed 10 December 201).

References to ongoing studies

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
  6. References to other published versions of this review
NCT01466114 {unpublished data only}
  • NCT01466114. Estriol treatment in multiple sclerosis (MS): effect on cognition. clinicaltrials.gov/ct2/show/NCT01466114 (accessed 10 December 2013).

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
  6. References to other published versions of this review
Ahlemeyer 2003
Amato 2004
  • Amato MP, Bartolozzi ML, Zipoli V, Portaccio E, Mortilla M, Guidi L, et al. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology 2004;63(1):89-93.
Amato 2006
Bakshi 2003
Benedict 1997
  • Benedict R. Brief Visuospatial Memory Test-Revised: Professional Manual. Odessa, Florida: Psychological Assessment Resources, 1997.
Benedict 2005
  • Benedict RH, Zivadinov R, Carone DA, Weinstock-Guttman B, Gaines J, Maggiore C, et al. Regional lobar atrophy predicts memory impairment in multiple sclerosis. American Journal of Neuroradiology 2005;26(7):1824-31.
Benedict 2006
  • Benedict RH, Cookfair D, Gavett R, Gunther M, Munschauer F, Garg N, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). Journal of the International Neuropsychological Society 2006;12(4):549-58.
Benedict 2009
  • Benedict RH, Ramasamy D, Munschauer F, Weinstock-Guttman B, Zivadinov R. Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. Journal of Neurology Neurosurgery and Psychiatry 2009;80(2):201-6.
Boringa 2001
  • Boringa JB, Lazeron RH, Reuling IE, Adèr HJ, Pfennings L, Lindeboom J, et al. The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice. Multiple Sclerosis 2001;7(4):263-7.
Buschke 1974
  • Buschke H, Fuld PA. Evaluating storage, retention and retrieval in disordered memory and learning. Neurology 1974;24:1019-25.
Calabrese 2009
  • Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, Favaretto A, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Archives of Neurology 2009;66(9):1144-50.
Calabrese 2012
  • Calabrese M, Poretto V, Favaretto A, Alessio S, Bernardi V, Romualdi C, et al. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain 2012;135(Pt 10):2952-61.
Cella 1996
  • Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996;47(1):129-39.
Chiaravalloti 2008
Delis 2000
  • Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test. 2nd Edition. San Antonio: Psychological Corporation, 2000.
Dineen 2009
  • DineenRA, Vilisaar J, Hlinka J, Bradshaw CM, Morgan PS, Constantinescu CS, et al. Disconnection as a mechanism for cognitive dysfunction in multiple sclerosis. Brain 2009;132(Pt 1):239-49.
Feuillet 2007
  • Feuillet L, Reuter F, Audoin B, Malikova I, Barrau K, Cherif AA, et al. Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis 2007;13(1):124-7.
Fischer 1999
  • Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Multiple Sclerosis 1999;5(4):251-9.
Foong 1998
  • Foong J, Rozewicz L, Quaghebeur G, Thompson AJ, Miller DH, Ron MA. Neuropsychological deficits in multiple sclerosis after acute relapse. Journal of Neurology Neurosurgery and Psychiatry 1998;64(4):529-32.
Geurts 2012
  • Geurts JJ, Calabrese M, Fisher E, Rudick RA. Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurology 2012;11(12):1082-92.
Glanz 2012
  • Glanz BI, Healy BC, Hviid LE, Chitnis T, Weiner HL. Cognitive deterioration in patients with early multiple sclerosis: a 5-year study. Journal of Neurology Neurosurgery and Psychiatry 2012;83(1):38-43.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Huang 2004
  • Huang SH, Duke RK, Chebib M, Sasaki K, Wada K, Johnston GA. Ginkgolides, diterpene trilactones of Ginkgo biloba, as antagonists at recombinant alpha1beta2gamma2L GABAA receptors. European Journal of Pharmacology 2004;494:131-8.
Huijbregts 2004
  • Huijbregts SC, Kalkers NF, de Sonneville LM, de Groot V, Reuling IE, Polman CH. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology 2004;63(2):335-9.
Kinsinger 2010
  • Kinsinger SW, Lattie E, Mohr DC. Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis. Neuropsychology 2010;24(5):573-80.
Kuczenski 1995
  • Kuczenski R, Segal DS, Cho AK, Melega W. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. The Journal of Neuroscience 1995;15:1308-17.
Leocani 2000
  • Leocani L, Locatelli T, Martinelli V, Rovaris M, Falautano M, Filippi M, et al. Electroencephalographic coherence analysis in multiple sclerosis: correlation with clinical, neuropsychological, and MRI findings. Journal of Neurology Neurosurgery and Psychiatry 2000;69(2):192-8.
Lezak 2004
  • Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. 4th Edition. New York: Oxford University Press, 2004.
McDonald 2001
Mesaros 2012
  • Mesaros S, Rocca MA, Kacar K, Kostic J, Copetti M, Stosic-Opincal T, et al. Diffusion tensor MRI tractography and cognitive impairment in multiple sclerosis. Neurology 2012;78(13):969-75.
Morgen 2006
  • Morgen K, Sammer G, Courtney SM, Wolters T, Melchior H, Blecker CR, et al. Evidence for a direct association between cortical atrophy and cognitive impairment in relapsing-remitting MS. Neuroimage 2006;30(3):891-8.
Morrow 2011
  • Morrow SA, Jurgensen S, Forrestal F, Munchauer FE, Benedict RH. Effects of acute relapses on neuropsychological status in multiple sclerosis patients. Journal of Neurology 2011;258(9):1603-8.
Nathan 2000
Paulesu 1996
Pitt 2000
Polman 2005
Polman 2011
Poser 1983
Potagas 2008
  • Potagas C, Giogkaraki E, Koutsis G, Mandellos D, Tsirempolou E, Sfagos C, et al. Cognitive impairment in different MS subtypes and clinically isolated syndromes. Journal of the Neurological Sciences 2008;267(1-2):100-6.
Rao 1990a
  • Rao SM, in collaboration with the Cognitive Function Study Group of the National Multiple Sclerosis Society. A Manual for the Brief, Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis. Milwaukee: WI: Section of Neuropsychology, Medical College of Wisconsin, 1990.
Rao 1990b
  • Rao SM. Cognitive Function Study Group, NMSS. A Manual for the Brief Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis. New York: National Multiple Sclerosis Society, 1990.
Rao 1991a
  • Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991;41(5):685-91.
Rao 1991b
  • Rao SM, Leo GJ, Ellington MS, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis: II. Impact on employment and social functioning. Neurology 1991;41:692-6.
Rao 1991c
  • Rao SM. Neuropsychological Screening Battery for Multiple Sclerosis. Milwaukee, WI: Medical College of Wisconsin, 1991.
Rao 1993
  • Rao SM, Grafman J, DiGiulio D, Mittenberg W, Bernardin L, Leo GJ, et al. Memory dysfunction in multiple sclerosis: its relation to working memory, semantic encoding, and implicit learning. Neuropsychology 1993;7(3):364-74.
Review Manager 2012
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013.
Rossi 2012
  • Rossi F, Giorgio A, Battaglini M, Stromillo ML, Portaccio E, Goretti B, et al. Relevance of brain lesion location to cognition in relapsing multiple sclerosis. PLoS One 2012;7(11):e44826.
Ruberg 1987
  • Ruberg M, Villageois A, Bonnet AM, Rieger F, Agid Y, Fahn S. Acetylcholinesterase and butyrylcholinesterase activity in the cerebrospinal fluid of patients with neurodegenerative diseases involving cholinergic systems. Journal of Neurology Neurosurgery and Psychiatry 1987;50(5):538-43.
Ruet 2013
  • Ruet A, Deloire M, Charré-Morin J, Hamel D, Brochet B. Cognitive impairment differs between primary progressive and relapsing-remitting MS. Neurology 2013;80(16):1501-8.
Sanfilipo 2006
Schünemann 2009
  • Schünemann H, Brożek J, Oxman A, editors. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendation. Version 3.2 [updated March 2009]. The GRADE Working Group. http://www.cc-ims-net/gradepro 2009.
Smith 1982
  • Smith, A. Symbol Digit Modalities Test (SDMT). Los Angeles: Western Psychological Services, 1982.
Thornton 2002
Vercellino 2005
  • Vercellino M, Plano F, Votta B, Mutani R, Giordana MT, Cavalla P. Grey matter pathology in multiple sclerosis. Journal of Neuropathology and Experimental Neurology 2005;64(12):1101-7.
Vickrey 1995
Ware 1992
Wechsler 1987
  • Wechsler D. Wechsler Memory Scale-Revised. San Antonio: Psychological Corporation, 1987.
Wechsler 1997a
  • Wechsler D. Wechsler Memory Scale - Third Edition (WMS-III). San Antonio: Psychological Corporation, 1997.
Wechsler 1997b
  • Wechsler D. Wechsler Adult Intelligence Scale. 3rd Edition. San Antonio: The Psychological Corporation, 1997.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
  6. References to other published versions of this review
He 2011